In order to quantify the effects of tesaglitazar, a dual PPARa/g agonist, on serum lipoprotein-lipid levels, a 12 week, randomized, double-blind, placebo-controlled trial was performed in 390 subjects with abdominal obesity and elevated triglyceride levels. In this trial, four doses of tesaglitazar were tested: 0.1, 0.25, 0.5, and 1.0 mg/day. The main study finding was that tesaglitazar induced a dose-dependent decrease in the apolipoprotein (apo)B/apo AI ratio (and apo B and apo AI separately), apo CIII, and LDL particle concentration as measured by nuclear magnetic resonance. Although the development of tesaglitazar was stopped in May 2006 because of reversible elevations in the serum creatinine concentration with an associated decrease in glomerular filtration rate, this study highlights the potential benefits of dual PPARa/g agonism in improving the metabolic risk profile of non-diabetic subjects with insulin resistance and associated dyslipidemia.
Documentation centre